CMIC：2026年日本：市场进入、经验与关键机会报告（英文版）

Japan is increasingly seen as a favorable market and environment for global pharmaceutical drug development. Nevertheless, there is a lingering perception that Japan is too restrictive, limiting the ability of pharma companies—and especially of small biotechs—to conduct clinical trials and commercialize new therapies. In an effort to change that perception, Japan’s Pharmaceutical and Medical Device Agency (PMDA) has introduced several key regulatory reforms in recent years. Although the path to